07:49 EST MBX Biosciences (MBX) drops 4% in premarket trading after Goldman initiates with Sell
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- MBX Biosciences initiated with a Sell at Goldman Sachs
- MBX Biosciences, Inc.: Strong Financial Outlook and Strategic Direction Support Buy Rating
- MBX Biosciences Reports Q3 2025 Financial Results
- MBX Biosciences price target lowered to $77 from $84 at Guggenheim
- MBX Biosciences price target raised to $57 from $56 at Mizuho